[Unclear retinopathy after intravitreal injection of ocriplasmin]

Ophthalmologe. 2016 Feb;113(2):156-9. doi: 10.1007/s00347-015-0080-0.
[Article in German]

Abstract

Case report: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea® (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment.

Conclusion: Before injection of Jetrea® a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.

Keywords: Optical coherence tomography; Retina; Visual field; Visual loss; Vitreomacular traction.

Publication types

  • Case Reports

MeSH terms

  • Diagnosis, Differential
  • Female
  • Fibrinolysin / administration & dosage*
  • Fibrinolysin / adverse effects*
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Intravitreal Injections / adverse effects*
  • Middle Aged
  • Night Blindness / chemically induced*
  • Night Blindness / diagnosis*
  • Night Blindness / prevention & control
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / adverse effects*
  • Retinal Diseases
  • Vitreous Detachment / complications
  • Vitreous Detachment / drug therapy*

Substances

  • Fibrinolytic Agents
  • Peptide Fragments
  • microplasmin
  • Fibrinolysin